COVID-19News

Serum Institute delays expected launch of Novavax vaccine in India

Poonawalla recently said that the trials of Corovax had kicked off in India but did not say why the vaccine launch was delayed

The launch in India of a new COVID-19 vaccine developed jointly by the Serum Institute of India and US-based biotech firm Novavax is likely to be delayed to September, according to Adar Poonawalla, CEO, Serum.

THIS CAN BE YOUR ADVERTISEMENT

Poonawalla said in January that the vaccine, named Corovax, was expected to be launched by June. Poonawalla recently said that the trials of Corovax had kicked off in India but did not say why the vaccine launch was delayed.

“It has been tested against African and UK variants of #COVID19 and has an overall efficacy of 89 per cent,” tweeted Poonawalla, whose Serum Institute is the world’s largest manufacturer of vaccines.

“Hope to launch by September 2021!”

Poonawalla said earlier this month that a temporary US ban on exports of critical raw materials could limit the production of coronavirus vaccines such as Novavax.

India, the world’s biggest vaccine maker, said it would prioritise domestic COVID-19 inoculations amid rising coronavirus case and had told international buyers of its decision.

Reuters

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close